KR20170122762A - 혈관신생 억제용 펩타이드 - Google Patents

혈관신생 억제용 펩타이드 Download PDF

Info

Publication number
KR20170122762A
KR20170122762A KR1020177024830A KR20177024830A KR20170122762A KR 20170122762 A KR20170122762 A KR 20170122762A KR 1020177024830 A KR1020177024830 A KR 1020177024830A KR 20177024830 A KR20177024830 A KR 20177024830A KR 20170122762 A KR20170122762 A KR 20170122762A
Authority
KR
South Korea
Prior art keywords
peptide
hours
vegf
neovascularization
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177024830A
Other languages
English (en)
Korean (ko)
Inventor
율리아 에이. 코마로바
마크 로젠버트
아스라 비. 말릭
Original Assignee
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 filed Critical 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Publication of KR20170122762A publication Critical patent/KR20170122762A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/102—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for optical coherence tomography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
    • A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
    • A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
    • A61B3/1241—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00844—Feedback systems
    • A61F2009/00851—Optical coherence topography [OCT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00863—Retina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00865—Sclera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00872—Cornea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020177024830A 2015-03-02 2016-03-02 혈관신생 억제용 펩타이드 Ceased KR20170122762A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126968P 2015-03-02 2015-03-02
US62/126,968 2015-03-02
PCT/US2016/020443 WO2016141053A1 (en) 2015-03-02 2016-03-02 Peptides for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
KR20170122762A true KR20170122762A (ko) 2017-11-06

Family

ID=55543089

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177024830A Ceased KR20170122762A (ko) 2015-03-02 2016-03-02 혈관신생 억제용 펩타이드

Country Status (18)

Country Link
US (2) US9675660B2 (enExample)
EP (1) EP3265110B1 (enExample)
JP (1) JP6896641B2 (enExample)
KR (1) KR20170122762A (enExample)
CN (1) CN107427549B (enExample)
AU (1) AU2016226264B2 (enExample)
BR (1) BR112017018665A2 (enExample)
CA (1) CA2977389A1 (enExample)
DK (1) DK3265110T3 (enExample)
ES (1) ES2820710T3 (enExample)
IL (1) IL253966B (enExample)
MX (1) MX2017011170A (enExample)
PH (1) PH12017501549B1 (enExample)
PL (1) PL3265110T3 (enExample)
RU (1) RU2708375C2 (enExample)
SG (1) SG11201706799YA (enExample)
WO (1) WO2016141053A1 (enExample)
ZA (1) ZA201705934B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024181833A1 (ko) * 2023-02-27 2024-09-06 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020053773A1 (en) * 2018-09-11 2020-03-19 Anbition S.R.L. Peptides and medical uses thereof
KR20210062649A (ko) * 2018-09-11 2021-05-31 앤비션 에스.알.엘. 펩티드 및 이의 의학적 용도
CN113755634A (zh) * 2021-10-12 2021-12-07 河南省农业科学院烟草研究所 一种鸢尾丝囊霉菌分子检测的特异引物及其检测方法
CN115737677B (zh) * 2022-07-25 2024-09-06 天津医科大学总医院 一种多肽修饰的金纳米颗粒在制备抑制糖尿病视网膜病变药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
GB9718609D0 (en) 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
CN101014358A (zh) * 2003-10-29 2007-08-08 约翰·霍普金斯大学 色素上皮所衍生因子的生物活性及使用方法
EP1689355A4 (en) 2003-11-06 2008-10-01 Res Dev Foundation SELECTIVE INHIBITORS OF NUCLEAR FACTOR KB ACTIVATION AND ITS USES
EP1786451A4 (en) * 2004-08-06 2009-07-22 Sopherion Therapeutics Inc ANTIANGIOGENIC PEPTIDES AND METHOD FOR THEIR USE
JP5548616B2 (ja) * 2007-08-08 2014-07-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆｒ−１／ｎｒｐ−１標的化ペプチド
BRPI0903901A2 (pt) * 2008-04-16 2017-05-23 Univ Of Utah Res Foudation composição, métodos para inibir permeabilidade vascular, angiogênese patológica, e um mais de ativação ou disponibilidade de rac, ativação ou disponibilidade de arf6, vazamento vascular, permeabilidade vascular, angiogênese patológica e inibição de sinalde múltiplos fatores angiogênicos, de permeabilidadee inflamatórios, e, métodos para preservação de função de barreira endotelial, e para bloqueio de sinalização de vegf a jusante do receptor de vegf
FR2940032B1 (fr) 2008-12-23 2013-08-09 Seb Sa Panier de cuisson d'aliments et systeme de cuisson correspondant
US20100190691A1 (en) 2009-01-27 2010-07-29 Trojan Technologies, Ltd Delivery of nucleic acids using cell-penetrating peptides
EP2439514A1 (en) 2010-10-01 2012-04-11 Aqsens Oy Method, apparatus, and system for examining optically a sample carried in a plurality of wells
WO2012174028A2 (en) * 2011-06-13 2012-12-20 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
CN102286101B (zh) * 2011-08-08 2013-05-08 常州亚当生物技术有限公司 抗VEGF单克隆抗体Fab片段Vasculizumab及其应用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024181833A1 (ko) * 2023-02-27 2024-09-06 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물

Also Published As

Publication number Publication date
MX2017011170A (es) 2018-04-24
SG11201706799YA (en) 2017-09-28
AU2016226264A1 (en) 2017-08-31
US9675660B2 (en) 2017-06-13
RU2017133101A (ru) 2019-04-02
RU2708375C2 (ru) 2019-12-06
PL3265110T3 (pl) 2020-12-28
IL253966B (en) 2019-12-31
ZA201705934B (en) 2018-12-19
JP6896641B2 (ja) 2021-06-30
PH12017501549B1 (en) 2021-12-15
HK1247573A1 (zh) 2018-09-28
CN107427549A (zh) 2017-12-01
IL253966A0 (en) 2017-10-31
ES2820710T3 (es) 2021-04-22
EP3265110B1 (en) 2020-07-15
EP3265110A1 (en) 2018-01-10
CN107427549B (zh) 2022-01-11
AU2016226264B2 (en) 2021-04-01
US20160256518A1 (en) 2016-09-08
PH12017501549A1 (en) 2018-02-05
BR112017018665A2 (pt) 2018-04-24
JP2018508528A (ja) 2018-03-29
DK3265110T3 (da) 2020-10-19
RU2017133101A3 (enExample) 2019-07-26
HK1248101A1 (zh) 2018-10-12
US10064911B2 (en) 2018-09-04
WO2016141053A1 (en) 2016-09-09
CA2977389A1 (en) 2016-09-09
US20170258868A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
CN109715189B (zh) 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
JP6585720B2 (ja) 眼疾患治療のペプチド及びこれを含む眼疾患治療用組成物
US10064911B2 (en) Peptides for treating cancer
EP3278810A1 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
AU2015226911A1 (en) Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain
JP2022514778A (ja) 筋膜損傷の予防および治療におけるアネキシンの使用
CN109789180B (zh) Kif13b衍生的肽和抑制血管生成的方法
CN107629114B (zh) 多肽、其衍生物及其在制备抗肺纤维化的药物中的应用
ES2713068T3 (es) Derivados de IGFBP-3 y usos de los mismos
CN106188232B (zh) 肽组合物和治疗肺损伤、哮喘、过敏反应、血管性水肿、全身血管通透综合征和鼻塞的方法
US8389476B2 (en) Parstatin peptides and uses thereof
WO2019133950A1 (en) Smad7 for treatment and prevention of posterior capsule opacification
JP7830567B2 (ja) ペプチドおよびその医学的使用
WO2008120263A2 (en) Prokineticins receptors antagonists, derivatives and uses thereof
CN111201247A (zh) 治疗方法和新颖构建体
HK1248101B (en) Peptides for inhibiting angiogenesis
HK1247573B (en) Peptides for inhibiting angiogenesis
EP4454705A1 (en) Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and metaplasia of retinal pigment epithelium (rpe) cells
KR20150010957A (ko) 넓은 스펙트럼 erbb 리간드 결합 분자 및 그의 사용 방법
CN113015539B (zh) 肽及其医学用途
WO2025056713A1 (en) Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and/or metaplasia of retinal pigment epithelium (rpe) cells
HK40030406A (en) Methods of treatment and novel constructs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170904

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210223

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230515

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231006

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230515

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I